WASHINGTON--Perspectum awarded new FDA research grant to evaluate biomarker for use in rare disease treatment.

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...

SiPhox Health, with MIT roots, is developing a home blood testing device using a silicon photonic chip, yet to be FDA ...

Explore how the platelet-to-albumin ratio correlates with disease activity in early rheumatoid arthritis, potentially serving ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

“We need future studies to help us understand the relationship between cholesterol variability and dementia risk,” she said ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

A new study reveals that changes in gut microbial load, influenced by factors like diet, age, and antibiotics, drive the presence of bacteria previously linked to diseases such as inflammatory bowel ...

Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

With ALTO-300’s existing validation for depression in Europe and the use of an EEG-defined biomarker, Skorney anticipates a positive outcome that could boost Alto’s valuation and reinforce confidence ...